Literature DB >> 21339097

Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.

Theresa L Whiteside1, Magis Mandapathil, Miroslaw Szczepanski, Marta Szajnik.   

Abstract

Human tumors utilize many different mechanisms of immunosuppression to prevent immune cells from exercising their antitumor activities. These mechanisms, which enable the tumor to escape from the host immune system and to progress, are being intensively investigated in hope of finding therapeutically safe and effective inhibitors able to counteract tumor-induced immunosuppression. Three of more recently discovered tumor-related suppression mechanisms, i.e. accumulations of adenosine-producing regulatory T-cells (Treg) in the tumor microenvironment, release by tumors of suppressive microvesicles (TMV) and expression of toll-like receptors (TLR) on the tumor cell surface, are described in this review. All contribute in a varying degree to creating a milieu favorable for the tumor and unfavorable for immune effector cells. Tumor escape has been a major problem in cancer immunotherapy and it has been held responsible for the failure of many immune interventions in cancer. For this reason, it is important to study and understand the various suppressive pathways human tumors utilize. Future antitumor immunotherapies are likely to include inhibitors of tumor-induced suppression with the goal of restoring antitumor immune responses in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339097     DOI: 10.1684/bdc.2010.1294

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  29 in total

1.  Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages.

Authors:  Fatemeh Momen-Heravi; Shashi Bala; Terence Bukong; Gyongyi Szabo
Journal:  Nanomedicine       Date:  2014-03-29       Impact factor: 5.307

2.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

Review 3.  Novel therapies for metastatic castrate-resistant prostate cancer.

Authors:  Farshid Dayyani; Gary E Gallick; Christopher J Logothetis; Paul G Corn
Journal:  J Natl Cancer Inst       Date:  2011-09-13       Impact factor: 13.506

4.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

5.  Exosomal tumor microRNA modulates premetastatic organ cells.

Authors:  Sanyukta Rana; Kamilla Malinowska; Margot Zöller
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 6.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).

Authors:  Theresa L Whiteside
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

Review 7.  Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment.

Authors:  Ramin Lotfi; Christof Kaltenmeier; Michael T Lotze; Christoph Bergmann
Journal:  Transfus Med Hemother       Date:  2016-03-08       Impact factor: 3.747

Review 8.  Extracellular Vesicles and Their Current Role in Cancer Immunotherapy.

Authors:  Carla Giacobino; Marta Canta; Cristina Fornaguera; Salvador Borrós; Valentina Cauda
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  Ganoderma lucidum polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation.

Authors:  Li-Xin Sun; Zhi-Bin Lin; Xin-Suo Duan; Jie Lu; Zhi-Hua Ge; Min Li; En-Hong Xing; Tian-Fei Lan; Miao-Miao Jiang; Ning Yang; Wei-Dong Li
Journal:  Exp Ther Med       Date:  2013-01-29       Impact factor: 2.447

10.  Immune responses to cancer: are they potential biomarkers of prognosis?

Authors:  Theresa L Whiteside
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.